Screener
R&D at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Dyne Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215702
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $100,889 | $106,447 |
| General and administrative | 24,387 | 15,925 |
| Total operating expenses | 125,276 | 122,372 |
| Loss from operations | (125,276) | (122,372) |
| Other income (expense): | ||
| Interest income | 8,757 | 7,100 |
| Interest expense | (4,202) | — |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dyne Therapeutics, Inc.'s R&D?
- Dyne Therapeutics, Inc. (DYN) reported R&D of $100.89M in Q1 2026.
- How has Dyne Therapeutics, Inc.'s R&D changed year-over-year?
- Dyne Therapeutics, Inc.'s R&D decreased by 5.2% year-over-year, from $106.45M to $100.89M.
- What is the long-term trend for Dyne Therapeutics, Inc.'s R&D?
- Over 4 years (2021 to 2025), Dyne Therapeutics, Inc.'s R&D has grown at a 34.6% compound annual growth rate (CAGR), from $121.31M to $398.33M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Dyne Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude